Gross RE. Breast cancer: risk factors, screening, and prevention. Semin Oncol Nurs. 2000;16(3):176–84.

Article  PubMed  CAS  Google Scholar 

Schwartz GF, Hughes KS, Lynch HT, Fabian CJ, Fentiman IS, Robson ME, et al. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April 2007. Breast J. 2009;15(1):4–16.

Article  PubMed  Google Scholar 

Singletary SE. Rating the risk factors for breast cancer. Ann Surg. 2003;237(4):474–82.

Article  PubMed  PubMed Central  Google Scholar 

Obeagu EI, Obeagu GU. Breast cancer: a review of risk factors and diagnosis. Medicine (Baltimore). 2024;103(3): e36905.

Article  PubMed  CAS  Google Scholar 

Force UPST. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;331(22):1918–30.

Article  Google Scholar 

Drug Approvals and Databases. U.S. Food and Drug Administration. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases.

Vañó-Galván S, Hermosa-Gelbard Á, Sánchez-Neila N, Miguel-Gómez L, Saceda-Corralo D, Rodrigues-Barata R, et al. Treatment of recalcitrant adult alopecia areata universalis with oral azathioprine. J Am Acad Dermatol. 2016;74(5):1007–8.

Article  PubMed  Google Scholar 

Bardek I, Milavec-Puretić V, Lipozencić J. Azathioprine in dermatology. Acta Dermatovenerol Croat. 2007;15(4):264–8.

PubMed  CAS  Google Scholar 

Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177(11):1296–305.

Article  PubMed  Google Scholar 

Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case–control study. Off J Am Coll Gastroenterol. 2010;105(7):1604–9.

Article  CAS  Google Scholar 

Mamtani R, Clark AS, Scott FI, Brensinger CM, Boursi B, Chen L, et al. Association between breast cancer recurrence and immunosuppression in rheumatoid arthritis and inflammatory bowel disease: a cohort study. Arthritis Rheumatol. 2016;68(10):2403–11.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sebela Pharmaceuticals Inc. IMURAN (azathioprine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/016324s040lbl.pdf. Revised July 2024. Accessed 4 Jan 2025.

Strazzulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15–24.

Article  PubMed  Google Scholar 

Liu W, Wang L, Meng D, Hong C, Zhang Q, Yang J. Effectiveness of topical corticosteroids on the prevention of acute radiation dermatitis in patients with breast cancer: An updated systematic review and meta-analysis. Asia Pac J Oncol Nurs. 2024;11(9): 100553.

Article  PubMed  PubMed Central  Google Scholar 

Tam S, Zhou G, Trombetta M, Caini S, Ryan Wolf J, van den Hurk C, et al. Topical corticosteroids for the prevention of severe radiation dermatitis: a systematic review and meta-analysis. Support Care Cancer. 2023;31(7):382.

Article  PubMed  Google Scholar 

Haruna F, Lipsett A, Marignol L. Topical management of acute radiation dermatitis in breast cancer patients: a systematic review and meta-analysis. Anticancer Res. 2017;37(10):5343–53.

PubMed  Google Scholar 

Gollob MH, Dekoven JG, Bell MJ, Assaad D, Rao J. Postradiation morphea. J Rheumatol. 1998;25(11):2267–9.

PubMed  CAS  Google Scholar 

Sørensen HT, Mellemkjær L, Skriver MV, Lash TL, Olsen JH, Baron JA. No excess risk of breast cancer among female users of systemic glucocorticoids. Cancer Epidemiol Biomark Prev. 2005;14(4):1022–3.

Article  Google Scholar 

Sørensen GV, Cronin-Fenton DP, Sørensen HT, Ulrichsen SP, Pedersen L, Lash TL. Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study. Breast Cancer Res. 2012;14(1):R21.

Article  PubMed  PubMed Central  Google Scholar 

Cairat M, Al Rahmoun M, Gunter MJ, Heudel PE, Severi G, Dossus L, et al. Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women. BMC Med. 2021;19(1):186.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Safarini OA, Keshavamurthy C, Patel P. Calcineurin inhibitors. StatPearls [Internet]: StatPearls Publishing; 2023.

Husein-ElAhmed H, Steinhoff M. Efficacy and predictive factors of cyclosporine A in alopecia areata: a systematic review with meta-analysis. J Dermatol Treat. 2022;33(3):1643–51.

Article  CAS  Google Scholar 

Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123–30.

Article  PubMed  Google Scholar 

Lai VWY, Chen G, Gin D, Sinclair R. Cyclosporine for moderate-to-severe alopecia areata: a double-blind, randomized, placebo-controlled clinical trial of efficacy and safety. J Am Acad Dermatol. 2019;81(3):694–701.

Article  PubMed  CAS  Google Scholar 

Lebwohl M, Ellis C, Gottlieb A, Koo J, Krueger G, Linden K, et al. Cyclosporine consensus conference: With emphasis on the treatment of psoriasis. J Am Acad Dermatol. 1998;39(3):464–75.

Article  PubMed  CAS  Google Scholar 

Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010;63(6):949–72.

Article  PubMed  CAS  Google Scholar 

Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–86.

Article  PubMed  CAS  Google Scholar 

Novartis Pharmaceuticals Corporation. NEORAL (cyclosporine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf. Revised Semptember 2023. Accessed 5 Jan 2025.

Novartis Pharmaceuticals Corporation. SANDIMMUNE (cyclosporine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050573s039,050574s047,050625s053lbl.pdf. Revised Semptember 2023. Accessed 5 Jan 2025.

Stewart T, Tsai SC, Grayson H, Henderson R, Opelz G. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. The Lancet. 1995;346(8978):796–8.

Article  CAS  Google Scholar 

Jiang K, He B, Lai L, Chen Q, Liu Y, Guo Q, et al. Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. Int J Mol Med. 2012;30(2):302–8.

Article  PubMed  CAS  Google Scholar 

Institute NC. Evaluating the Effects of Cyclosporine A on Cancer Growth Markers in Patients with DNA Repair Defective Triple-negative Breast Cancer. 2024 [cited; Available from: https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-01558&r=1. Accessed 15 Nov 2024.

Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011;13(4):215.

Article  PubMed  PubMed Central  Google Scholar 

Bulock KG, Cardia JP, Pavco PA, Levis WR. Diphencyprone treatment of alopecia areata: postulated mechanism of action and prospects for therapeutic synergy with RNA interference. J Investig Dermatol Symp Proc. 2015;17(2):16–8.

Article  PubMed  Google Scholar 

Desai DD, Buontempo MG, Nohria A, Alhanshali L, Lo Sicco K, Shapiro J. Use of diphenylcyclopropenone for alopecia areata treatment during pregnancy. JAAD Case Rep. 2024;48:88–9.

Article  PubMed  PubMed Central  Google Scholar 

Kutlubay Z, Sevim A, Aydın Ö, Vehid S, Serdaroğlu S. Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata. Turk J Med Sci. 2020;50(8):1817–24.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Berth-Jones J, Mc Burney A, Hutchinson PE. Diphencyprone is not detectable in serum or urine following topical application. Acta Derm Venereol. 1994;74(4):312–3.

Article  PubMed  CAS